Search company, investor...

ARCA Biopharma

arcabio.com

Founded Year

2005

Stage

PIPE - II | IPO

Market Cap

0.03B

Stock Price

2.23

Revenue

$0000 

About ARCA Biopharma

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Denver, Colorado.

Headquarters Location

8001 Arista Place Suite 200

Broomfield, Colorado, 80021,

United States

720-940-2200

Missing: ARCA Biopharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ARCA Biopharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ARCA Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ARCA Biopharma is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

ARCA Biopharma Patents

ARCA Biopharma has filed 17 patents.

The 3 most popular patent topics include:

  • Amines
  • Beta blockers
  • Antiarrhythmic agents
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/8/2021

1/17/2023

Beta blockers, Antiarrhythmic agents, Diabetes, Potassium channel blockers, Cardiac arrhythmia

Grant

Application Date

2/8/2021

Grant Date

1/17/2023

Title

Related Topics

Beta blockers, Antiarrhythmic agents, Diabetes, Potassium channel blockers, Cardiac arrhythmia

Status

Grant

Latest ARCA Biopharma News

James Flynn Joins ARCA biopharma Board of Directors

Dec 19, 2022

December 19, 2022 16:05 ET Westminster, Colorado, UNITED STATES WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Nerium Capital LLC is the General Partner of Nerium Partners LP, a healthcare focused investment partnership. Mr. Flynn also currently serves as a Board Member for Axiom Health, a provider of software and big-data solutions to the healthcare industry, since 2022, and has been an advisor to the company since 2020. From 2017 to 2018, Mr. Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm. Prior to that, from 2003 to 2017, Mr. Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr. Flynn worked in the credit research/high yield group at Putnam Investments, an investment firm. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT). Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder. In June 2022, the Company entered into a Cooperation Agreement with Cable Car Capital LLC and its affiliates that includes, among other terms, customary standstill provisions and the right for Cable Car to nominate an additional director nominee at the Company’s 2022 Annual Stockholder Meeting. The Company and Cable Car initiated a process and subsequently identified a mutually acceptable second independent director, Mr. Flynn, to join the Company’s Board of Directors. Mr. Flynn was elected as Director at the 2022 annual meeting of stockholders. About ARCA biopharma ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. At present, ARCA is evaluating options for development of its assets, including partnering and other strategic options. For more information, please visit www.arcabio.com . Investor & Media Contact:

ARCA Biopharma Frequently Asked Questions (FAQ)

  • When was ARCA Biopharma founded?

    ARCA Biopharma was founded in 2005.

  • Where is ARCA Biopharma's headquarters?

    ARCA Biopharma's headquarters is located at 8001 Arista Place, Broomfield.

  • What is ARCA Biopharma's latest funding round?

    ARCA Biopharma's latest funding round is PIPE - II.

  • Who are the investors of ARCA Biopharma?

    Investors of ARCA Biopharma include Boulder Ventures, Atlas Venture, InterWest Partners, Skyline Ventures, Peierls Foundation and 4 more.

  • Who are ARCA Biopharma's competitors?

    Competitors of ARCA Biopharma include Arena Pharmaceuticals, Adamas Pharmaceuticals, CoMentis, Pulmatrix, IVERIC bio and 11 more.

Compare ARCA Biopharma to Competitors

M
Metastatix

Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

C
Corimmun

focused on the development of therapeutics for the treatment of congestive heart failure and atherosclerosis.

A
Aqumen Biopharmaceuticals

The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degeneration (AMD). and iii)A0006 . Company is in negotiations to acquire rights to a Phase II program by year end 2007. The following diagram summarizes the important existing and anticipated clinical development milestones for each of the programs as they relate to their respective targeted applications:

T
Terapio

Terapio is a biopharmaceutical company specializing in the development of a pipeline of therapies based on the transport protein, RLIP76.

A
AlphaGEN

The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.